What's new? Log in Free sign up

Filing search / Nkarta, Inc. / "Goals"

Search information

Nkarta, Inc.

Companies

"Goals"

Keywords

SEC filings

Source

Export list of results

Export a CSV file of filings or unique companies (up to first 5,000 results).

Download list of filings Download list of companies

20 results

Newest first Best match first

NKTX Nkarta, Inc.

Quarterly report

of FDA-regulated products. Specifically, actions plans must include the sponsor’s goals for enrollment, the underlying rationale for those goals

13 Aug 24

4:08pm

NKTX Nkarta, Inc.

Quarterly report

populations in late-stage clinical trials of FDA-regulated products. Specifically, actions plans must include the sponsor’s goals for enrollment … , the underlying rationale for those goals and an explanation of how the sponsor intends to meet them. In addition to these requirements, the legislation

9 May 24

4:14pm

NKTX Nkarta, Inc.

goals to complete the review of BLAs. This is typically ten months from the date that the FDA accepts the BLA for filing for standard review BLAs … of FDA-regulated products. Specifically, actions plans must include the sponsor’s goals for enrollment, the underlying rationale for those goals

21 Mar 24

4:23pm

NKTX Nkarta, Inc.

Quarterly report

-stage clinical trials of FDA-regulated products. Specifically, actions plans must include the sponsor’s goals for enrollment, the underlying rationale … for those goals and an explanation of how the sponsor intends to meet them. In addition to these requirements, the legislation directs the FDA to issue

9 Nov 23

4:19pm

NKTX Nkarta, Inc.

Quarterly report

goals for enrollment, the underlying rationale for those goals and an explanation of how the sponsor intends to meet them. In addition

10 Aug 23

7:15am

Quarterly report

11 May 23

4:19pm

17 Mar 22

4:21pm

4s0s7gko2b8 si0

Nkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed/Refractory B Cell Malignancies

cjf5c3jfm2 clv5

Definitive proxy

Prospectus supplement with pricing info

8o8zq5sj4sto90j0j q1

IPO registration (amended)

9 Jul 20

3:26pm

bu1uzv6nn 9gf73

IPO registration (amended)

8 Jul 20

9:54pm

IPO registration (amended)

IPO registration (amended)

IPO registration

22j rmui3gvia1pk

IPO registration

3ge7 6e0fupmfs6

Draft registration statement (amended)

Draft registration statement (amended)

Draft registration statement

Prev
1
Next

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.